JCPenney Gets $2.25...
Health Care: Drugs
Emergent BioSolutions Incorporated (EBS: NYSE)
$14.26 0.01 | 0.07%
05/23/13 - 04:03 PM ET
Portfolios with EBS
- Portfolio NameUser Type
- UserGFNN Stockdiagnostics 12
- UserGFNN Stockdiagnostics 10
- Contributor9 Health Care Stocks With 1...
- UserRMF watchlist
- Userinvst2011
- UserDividend & Stable
- UserMSSB Trading
- UserPART 2 JPMorgan 28th Annual...
- Userdurfee
- UserBEN COLLEGE
Latest EBS Headlines from TheStreet
- July Options Now Available For Emergent BioSolutions (EBS) 05.20.13 | 05:05 pm
- Emergent BioSolutions Breaks Above 200-Day Moving Average - Bullish For EBS 04.17.13 | 04:04 pm
- TheStreet Ratings Top 10 Rating Changes 03.25.13 | 01:03 pm
- Emergent BioSolutions Incorporated Stock Downgraded (EBS) 03.21.13 | 05:03 am
- Stocks Under $10: Stealth Drug Play
08.29.12 | 06:08 am - Emergent BioSolutions' Management Presents At Wedbush 2012 Life Sciences Management Access Conference Call (Transcript) 08.14.12 | 01:08 pm
- Emergent BioSolutions' CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.02.12 | 10:08 pm
- Emergent BioSolutions' CEO Hosts Annual Shareholder Meeting Conference (Transcript) 05.17.12 | 01:05 pm
- Emergent BioSolutions Incorporated Stock Downgraded (EBS) 05.09.12 | 05:05 am
- Emergent BioSolutions CEOs Discuss 1Q 2012 Results - Earnings Call Transcript 05.04.12 | 12:05 am
Press Releases for EBS
- Emergent BioSolutions Reports Financial Results For Fourth Quarter And Full Year 2012 - Business Wire 03.07.13 | 04:03 pm
- Emergent BioSolutions To Present At Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.11.13 | 07:02 am
- Data From Historic Phase IIb Clinical Trial For Tuberculosis Vaccine Candidate MVA85A Published In The Lancet - Business Wire 02.04.13 | 07:02 am
- Emergent BioSolutions To Release Fourth Quarter And Full Year 2012 Financial Results And Conduct A Conference Call On March 7, 2013 - Business Wire 02.01.13 | 07:02 am
- Emergent BioSolutions Initiates Phase 2 Study In Pursuit Of A Post-Exposure Prophylaxis Indication For BioThrax - Business Wire 01.22.13 | 07:01 am
- Emergent BioSolutions Initiates Phase 2 Clinical Trial For Next Generation Anthrax Vaccine NuThrax - Business Wire 01.17.13 | 07:01 am
- Emergent BioSolutions Announces Preliminary 2012 Financial Results And Provides Guidance For 2013 - Business Wire 01.07.13 | 07:01 am
- Emergent’s TRU-016 For CLL Receives Orphan Medicinal Product Designation From European Commission - Business Wire 01.02.13 | 07:01 am
- Emergent BioSolutions Secures Exclusive U.S. Commercial Rights To Next Generation Pandemic Influenza Vaccine Candidate - Business Wire 12.28.12 | 12:12 pm
- Emergent BioSolutions To Present At 31st Annual J.P. Morgan Healthcare Conference - Business Wire 12.03.12 | 07:12 am
Partner Headlines for EBS
- Biodefense: Live By Government Contracts, Die By Government Contracts - Seeking Alpha 05.12.13 | 08:05 am
- Emergent BioSolutions Earnings: Here’s Why the Stock is Rising Now - Wall St. Cheat Sheet 05.02.13 | 08:05 am
- After-Hours Earnings Report for March 7, 2013 : HRB, COO, THO, P, FNSR, WX, ZQK, MAIN, EBS, SQNM, CMTL, CPK - NASDAQ 03.07.13 | 07:03 pm
- Emergent Inks Deal with VaxInnate - Analyst Blog - Zacks 12.31.12 | 03:12 pm
- Emergent Biosolutions Secures Exclusive US Commercial Rights to NextGen Pandemic Influenza Vaccine Candidate - Benzinga 12.28.12 | 12:12 pm
- Is Johnson & Johnson A Strong Buy Candidate? - Seeking Alpha 03.23.12 | 05:03 pm
- Company News for October 7, 2011 - Corporate Summary - Zacks 10.07.11 | 10:10 am
- Progress Software Reports Positive Quarter, Poor Guidance - Benzinga 09.27.11 | 04:09 pm
- Fisher Investments' Healthcare Picks: Large Caps Trumping Small Caps - Seeking Alpha 07.14.11 | 09:07 am
- Progress Software Roll Over in the After-Hours - Benzinga 06.28.11 | 04:06 pm
